i-RNA is a UWO spin-off established by Dr. Subrata Chakrabarti and Dr. Ting Ling in April 2024, in London Ontario, driven by a passion for scientific discovery and a commitment to patient care. We are developing a gene therapy targeting long non-coding RNA HOTAIR can be used to treat diabetic retinopathy(DR). Furthermore, this treatment can be used both as intraocular injection and as an eyedrop. Diabetic retinopathy is a main cause of blindness worldwide in the working age population. If successful, this technology will prevent blindness in the diabetics. The project is based on solid scientific data. Furthermore, this technology will allow us to treat diabetic retinopathy using an eyedrop. No such treatment exists in the market now.
| Website | https://www.i-rna.ca/ |
| Employees | 3 (1 on RocketReach) |
| Industry | Pharmaceutical Manufacturing |
| Keywords | Gene Therapy, Rna Therapeutics, Genetic Medicine, Messenger Rna, Rna Interference, Targeted Therapy, Biotechnology, Molecular Biology, Gene Editing, Drug Discovery, Pharmaceutical Research, Personalized Medicine, Therapeutics, Scientific Research, Biomedical Research, Crispr |
Looking for a particular i-RNA Corporation employee's phone or email?
i-RNA Corporation Questions
1 people are employed at i-RNA Corporation.
